Category: Medicine
Pollution as Growth Killer
India’s Outlook Business has an excellent issue focusing on pollution not just as a people killer but as a growth killer (as I have emphasized pollution reduces wealth and health, see especially this video).
I am interviewed; here is one bit:
Q. Doesn’t the demographic dividend argue for growth first?
The demographic dividend is people. If you poison the people, you shrink the dividend. A young workforce with lower cognitive scores, more respiratory illness and shorter working lives is a smaller asset than the headcount suggests, and the damage to today’s children shows up as lower productivity in future decades.
The premise also assumes that India’s pollution is a byproduct of economic growth. Much of it isn’t. Farmers burning rice stubble in Punjab and Haryana produce more smoke than GDP. Burning garbage, road dust and old coal plants running without scrubbers are not engines of the economy. Families cooking with wood and dung are polluting because they are poor. Cleaning up these sources costs very little output, and some of the fixes would raise it.
Bad air is a tax on talent. And not just Indian talent. Who wants to visit Delhi in November? Foreign skilled professionals, firms and tourists all have options. Clear skies are a selling point for incredible India.
See also Anumita Roychowdhury, executive director of research and advocacy at the Centre for Science and Environment, who argues:
The evidence increasingly shows that air pollution is imposing significant economic and health costs on India. Several studies from credible institutions have estimated the scale of these losses.
For instance, a Lancet study estimated that air pollution was costing India roughly 9.5% of its GDP. The World Bank has put the figure at around 6% of GDP, while a Dalberg [a consultancy] study highlighted substantial losses to Indian businesses, estimating the costs at around 3% of GDP.
The economic impact is visible in several ways. When people fall ill, there is a significant loss of productivity. We have also seen reports of reduced consumer footfall during periods of severe pollution in Delhi. There are also concerns about people shifting their base and businesses, raising questions about operating in highly polluted locations such as Delhi.
So, the evidence increasingly suggests that pollution is under-mining economic activity. We may talk about economic growth, but if a significant part of that growth is being eroded by pollution-related health and productivity losses, the gains are not being fully realised.
Expensive Pharmaceuticals for Targeted Diseases
My latest paper, The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine, is in the Journal of Law, Medicine and Ethics. I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure. We are going to get many more of these drugs in the future–more value but smaller patient group–so this paper is timely.
The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative. Pharmaceuticals are a hit-driven industry: most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment. Precision medicine intensifies this logic through two core economic challenges: (1) the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem; and (2) the “targeting dilemma,” in which precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate. Rather than simply controlling prices, the paper proposes a policy toolkit that includes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. The aim is to preserve innovation while expanding patient access.
As predicted, the ACA exchanges seem not to be stable
The average price of health insurance in the Obamacare marketplaces will rise by 13 percent next year, according to an analysis on Friday by KFF, the health research group.
The Trump administration on Friday published new prices for 2027 in 30 states with markets managed by the federal government. Using that data and state figures, KFF calculated the increase nationwide.
…The average cost for the cheapest bronze plan with a high deductible will be about $700 a month for a 50-year-old single person, according to Ms. Cox.
Here is more from the NYT. Of course that makes the people who can expect to be healthy all the less likely to sign up, given that the enforcement of the mandate, for political reasons, was forced to evolve into something quite weak. For purposes of context, when the original mandate was more tightly enforced, with actual penalties, the ACA was very unpopular and led to significant political protests. In essence the benefits to a broad, scattered majority were imposed on a well-identified minority, namely those who signed up because of the mandate. Trump in his first term relaxed mandate enforcement, thereby politically saving Obamacare at least for a while, but also creating this longer-term problem.
It is striking to me how infrequently I hear Democrats boasting about Obamacare. They instead prefer to talk as if little or nothing has been done for America’s uninsured.
Better Incentives, More Kidneys, More Lives
The organ procurement system has long been a miasma of inefficient monopoly providers. In 2024 I quoted some shocking facts from a great Statecraft interview with Jennifer Erickson and Greg Segal:
“Organs are literally lost and damaged in transit every single week. The OPTN contractor is 15 times more likely to lose or damage an organ in transit than an airline is a suitcase.”
Organs are not GPS-tracked!
“In an era when consumers can precisely monitor a FedEx package or a DoorDash dinner delivery, there are no requirements to track shipments of organs in real time — or to assess how many may be damaged or lost in transit.
“If Amazon can figure out when your paper towels and your dog food is going to arrive within 20 to 30 minutes, it certainly should be reasonable that we ought to track lifesaving organs, which are in chronic shortage,” Axelrod said.
Here’s one more astounding statistics:
“Seventeen percent of kidneys are offered to at least one deceased person before they are transplanted….”
Did you get that? The tracking system for patients is so dysfunctional that 17% of kidneys are offered to patients who are already dead–thus creating delays and missed opportunities.
Fortunately, even then there were changes in the works. In 2019 President Trump issued Executive Order 13879 to improve the performance of OPOs with better incentives and to allow living donors to recover more of their costs. The government being what it is, it has taken years to implement some of the new rules and enforcement of the OPO performance measures was deferred to 2026-2027. Nevertheless, there have been improvements. For example, many OPOs now GPS-track kidney transfers. And a new report estimates there have been significant gains from the changes.
- The Advancing American Kidney Health initiative was launched by President Donald Trump via Executive Order 13879 on July 10, 2019. In this Data Point, we estimate the range of increased growth in transplants that might be attributed to the policies launched through the Executive order and the economic value of that increased growth.
- The estimated impacts of the Executive Order (EO) range from a conservative 1,055 additional transplants annually to an upper estimate of 2,110 additional transplants. The range reflects variation in the counterfactuals used to compare with post-2019 transplant growth.
- Under the conservative-case scenario, the policy is estimated to be associated with approximately 23,214 additional kidney transplants between 2019 and 2040, generating about 147,410 life-years gained and 21,821 quality-adjusted life-years (QALYs) gained. Under the optimistic-case scenario, the policy is estimated to be associated with approximately 46,428 additional kidney transplants between 2019 and 2040, generating about 294,819 life-years gained and 43,643 quality-adjusted life-years (QALYs) gained.
The biggest and most consequential change would be to allow payment to living organ donors. The End Kidney Deaths Act, H.R. 2687, proposes a $50,000 refundable tax credit over five years for qualifying nondirected living kidney donors. The act has bipartisan support. Because dialysis is so expensive—and the federal government pays for much of it through Medicare’s special kidney-failure entitlement—the Act could save taxpayers money as well as saving lives.
Hat tip: The indefatigable Elaine Perlman.
Protecting Americans from Medicine
Max Doppelt: In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
A piece at KFF Health cover’s Max’s story and adds this insanity:
Rep. John Moolenaar (R-Mich.), who chairs the House Select Committee on the Chinese Communist Party, in June co-sponsored legislation with Rep. Debbie Dingell (D-Mich.) requiring all U.S. pharmaceutical deals with Chinese companies to be cleared by the Treasury Department.
Got that? A son flew to Shanghai to buy pharmaceuticals to extend his mother’s life and the House Select Committee on the Chinese Communist Party wants a Treasury lawyer monitoring the baggage claim. Yes, I am angry.
Addendum: See also my earlier post on Operation TrialBlazer and Montana’s SB535. My 2009 TED Talk is the ur-source for my argument that a rich China and India will create many benefits for the United States, including many more cancer drugs.
Does Costco Cause Cancer?
In December 2025, researchers led by Yazan Alwadi at Harvard’s T.H. Chan School of Public Health published a paper in Environmental Health that claimed to find that cancer incidence increased for people living closer to nuclear power plants in Massachusetts. In March, the same researchers published an expanded nationwide study claiming a similar result—this time looking at cancer mortality rates, rather than incidence—in Nature Communications. This was followed by a paper in the Journal of Exposure Science & Environmental Epidemiology that looked at associations of lung, breast, and colon cancers. Most recently, a study of total mortality, not just cancer, was published in the European journal Environmental Epidemiology.
The problem? Using the same methods pretty much everything causes cancer. An amazing takedown from Deric Tilson and Adam Stein:
For instance, living near a private four-year university is associated with a 15-fold increase in cancer mortality when compared to living near a nuclear power plant.
Costco has the largest effect of all the locations we have tested. Over 2.2 million cancer deaths can be attributed to Costco; that’s more than 20% of all cancer deaths between 2000 and 2018. Hot dogs, bulk spices, and reasonably priced clothes come with a cost.
What went wrong?
[The authors] chose nuclear power plants because a story could be built around that framework. When the researchers got positive results across our nation’s nuclear power plants, they didn’t check what their shiny new methodology would do using other landmarks. This is their pitfall: by taking the easy way out—getting results and making up a story around those results without double-checking their method—the authors could have no idea that what they were actually capturing was the methodology itself.
…The attributable number of deaths from this methodology is probably zero, but the attributable number of bad papers is at least four.
Do the elderly prefer robotic care?
The Japanese elderly, to be clear:
Population aging and shortages of long-term care workers have increased interest in care-giving robots and information and communication technology (ICT). This paper provides novel large-scale evidence on older individuals’ perceptions of such technologies, drawing on a custom-designed internet survey of 4,314 Japanese individuals aged 55 to 75. Respondents choose between two otherwise identical nursing homes: one in which all care is provided by human caregivers, and one in which robots and ICT are used to provide a substantial share of care in one randomly assigned domain (communication, monitoring, or mobility assistance), while other care remains human-provided. A majority of respondents (65 percent) prefer nursing homes where robots and ICT are used. Acceptance differs substantially across care domains: It is highest for mobility assistance, intermediate for monitoring, and lowest for communication. The average willingness to pay (WTP) for a nursing home where robots and ICT provide a substantial share of care is sizable, at 8 percent above the typical nursing home fee. Prior awareness of caregiving robots is positively associated with both acceptance and WTP, pointing to the potential role of information in shaping older individuals’ preferences. Acceptance and WTP are also strongly associated with sentiments toward robots and ICT expressed in attitude questions, providing support for the internal consistency of survey responses. A back-of-the-envelope calculation offers suggestive evidence that the benefits of introducing robots and ICT can be much larger than the costs, in particular for mobility-aid robots.
From a recent paper by Bertrand Achou, et.al.
Did the ACA reduce mortality?
Many of us brought up related points at the time, but basically we were booed off the reservation:
While recent research has provided evidence that the Medicaid expansions of the Affordable Care Act (ACA) reduced mortality, there is no evidence on the effect of the Affordable Care Act (ACA) net of the Medicaid expansions on mortality. This is an important gap in knowledge because the ACA significantly increased health insurance coverage in non-expansion states. In this article, we exploit the large increase in health insurance coverage brought forth by the ACA to examine the effect of the ACA and Medicaid expansions on mortality. Unlike prior studies that relied solely on geographic variation in Medicaid expansions to estimate the net effect of the expansion, we use a novel empirical approach that allows us to investigate the effect of the ACA net of Medicaid expansion on mortality, the incremental effect of the Medicaid expansion, and the overall effect of the ACA including Medicaid expansion. We use longitudinal data from the NHIS Linked Mortality Files (LMF) and a nationally representative sample of 40 to 58-year-olds combined with a difference-in-differences and a difference-in-differences-in-differences research design to obtain estimates of the effect of the ACA on mortality. We find no evidence that the Medicaid expansions had a beneficial effect on mortality but do find that the ACA net of Medicaid expansion reduced mortality.
That is from a new NBER working paper by
Is there now a better trend in youth mental health?
A key U.S. government report on mental health, substance use and addiction showed continued improvements in several metrics, especially among young people.
There was some uncertainty about the future of the National Survey on Drug Use and Health last year, when the entire 17-member team responsible for it was laid off by the Trump administration. But the Substance Abuse and Mental Health Services Administration released the latest report Monday, with data that lets researchers look at trends from 2021 to 2025.
Fewer adolescents aged 12 to 17 reported using tobacco, alcohol, marijuana and binge drinking in the previous month, the survey found.
And in the past year, fewer in that age group reported:
— illicit drug and marijuana use
— starting drinking alcohol, vaping or marijuana
— substance, alcohol or drug use disorders
Adolescents also saw declining trends for major depressive episodes and fewer reported serious thoughts of suicide, making a suicide plan and attempting suicide.
Here is the link, via Chris Ferguson.
No Doing, No Learning
A regulation that raises gasoline prices makes people angry but when regulation prevents an industry from ever existing, most people never learn what they lost.
Consider nuclear power. Overnight construction costs for early U.S. demonstration reactors fell 81 percent between 1954 and 1968. For reactors begun between 1967 and 1972, costs rose 187 percent. The 1971 Calvert Cliffs decision and then the reaction to Three Mile Island in 1979 accelerated the cost increases and slowed construction even more.
What might have happened had the earlier learning and deployment trends continued? Peter Lang’s 2017 paper in Energies estimates that nuclear power would have cost about one-tenth as much by 2015. The additional generation could have avoided as many as 9.5 million premature deaths.
The number is staggering even if quartered. Millions of deaths. Yet, the graveyard was both invisible and silent.
(Furthermore, climate change would not be a problem today had nuclear power not been handicapped.)
The nuclear story you probably know but Niko McCarty has an excellent new Works in Progress piece on an invisible graveyard of technology that I knew almost nothing about.
In the 1980s, officials decided to regulate engineered microbes under the Toxic Substances Control Act, a law written for industrial chemicals. Microbes swap genes all the time, but EPA treats them as “new” whenever DNA is introduced from another genus. As a result, even a marker gene used simply to identify successfully edited cells can trigger review if it remains in the organism. McCarty reports that researchers filed more than 240 applications between 1987 and 2018: “Only a few were ever approved for widespread use.”
What have we lost? We can’t know for sure but among the plausible losses McCarty discusses are engineered bacteria that detect buried explosives, microbes that extract rare-earth metals and improved plastic-digesting enzymes. Similarly, Chernia et al. write:
Promising many societal benefits, emergent products of biotechnology involve releasing genetically modified microbes (GMMs) into the environment. However, regulatory challenges limit their use. So far, GMMs have mainly been tested in agriculture and environmental cleanup, with few approved for commercial purposes. Current government regulations inadequately address modern genetic engineering and limit the potential of gut therapeutics, skin products, self-repairing materials, ocean pollution treatment, anti-corrosion coatings, etc.
And those are just some of the plausible first-stage losses. Perhaps even more importantly, we learn by doing. Thus, no doing, no learning. The first approved product is rarely the safest or the best but when we fail to approve the first we don’t get the much better 5th. Forty years of that process could have taken us well beyond the applications McCarty describes. We must build to build better.
Nuclear power at least left us enough reactors to get some idea of what we lost. With microbes, I needed McCarty to tell me there was something missing even though I study these issues for a living. And note one reason new microbe loss was invisible. No vote was ever taken. No debate was ever had. Officials in the 1980s reasoned that genomes are made of chemicals and chemicals are covered, and that doctrine has governed the field ever since despite being overly broad and excessively costly.
How many other gaps in our technology have explanations buried in the Federal Register?
—
Here is a video version of this post. Which do you like better?
Could our preoccupation with mental health be part of the problem?
Could our preoccupation with mental health be part of the problem?
In some ways, encouraging people to think and talk more about their mental health is a good thing. There is now less stigma around mental illness, and more people who can benefit from professional help are getting it. But there is also reason to believe that efforts to bring attention to mental health struggles are inadvertently making us more vulnerable to psychological distress.
Start with our expanding conception of mental illness. The more fixated we are on mental health, the more sensitive we become to anything that might qualify as a symptom and the more we use clinical language to describe normal emotional experiences like grief, burnout and loneliness. This broadening of what we think counts as a disorder — known as concept creep — encourages us to pathologize ordinary life and see ourselves as mentally unhealthy.
Here is more from Clay Routledge at the NYT.
The demand for human enhancement technologies
When a new technology promises large private benefits but may impose social costs that markets do not price, demand need not reveal how citizens want it governed. We examine this using a nationally representative U.S. survey experiment (N=5,556) on human enhancement technologies (HET). The experiment randomizes benefit domain, mechanism, heritability, purpose, and risk across vignettes; for each respondent’s assigned vignette, we elicit stated adoption, preferred regulation, and ethical and societal concerns. Overall, about 53% would adopt. Framing the technology as enhancing rather than restorative lowers adoption by about five percentage points, as much as a severe side-effect profile. About 28% would not adopt at any benefit. This refusal is driven overwhelmingly by the enhancing framing rather than by risk, consistent with a non-compensatory constraint for a substantial subgroup. Most who would adopt still favor strict regulation, and most who would never adopt do not wish to forbid others from doing so. Productivity enhancement generates the most ethical concern of any attribute but attracts the least regulation, and respondents favor subsidizing rather than taxing its adoption, consistent with a concern about access rather than safety. Private demand is therefore an unreliable guide to the governance citizens want, and the divergence we document provides a basis for regulators seeking to align the direction of technical change with societal values and priorities.
That is from a new NBER working paper by . And I will repeat this segment: “Productivity enhancement generates the most ethical concern of any attribute…” Do note of course that the last sentence of the authors is completely unwarranted, and is a classic example of underidentified political bias in academic reasoning.
Talk Therapy is Speech
IJ: On Wednesday, the United States District Court for the District of Columbia struck down a D.C. law that barred therapists from other jurisdictions from doing online teletherapy visits with clients in D.C. The decision comes nearly six years after Virginia-based counselor Elizabeth Brokamp teamed up with the Institute for Justice (IJ) to file a lawsuit arguing the law violated the First Amendment.
“This decision is a victory for anyone who speaks for a living,” said IJ Deputy Director of Litigation Robert McNamara. “Elizabeth’s victory here confirms that the First Amendment protects useful speech, including counseling, and that licensing boards can’t censor speech simply because someone doesn’t have their permission to talk.”
Congrats to the IJ! Now, we need to get rid of all the other bans on patients hiring physicians from other states. As I wrote last year:
During the pandemic, many restrictions on telemedicine were lifted, making it far easier for physicians to treat patients across state lines. That window has largely closed. Today, unless a doctor is separately licensed in a patient’s state—or the states have a formal agreement—remote care is often illegal. So if you live in Virginia and want a second opinion from a Mayo Clinic physician in Florida, you may have to fly to Florida, unless that Florida physician happens to hold a Virginia license.
The standard framing says this is a problem of physician licensing. That leads directly to calls for interstate compacts or federalizing medical licensure. Mutual recognition is good. Driver’s licenses are issued by states but are valid in every state. No one complains that Florida’s regime endangers Virginians. But mutual recognition or federal licensing is not the only solution nor the only way to think about this issue.
The real issue isn’t who licenses doctors. It’s that patients are forbidden from choosing a licensed doctor in another state. We can keep state-level licensing, but free the patient. Let any American consult any physician licensed in any state. That’s competitive federalism—no compacts, no federal agency, just patient choice.
Hat tip: Joel Selanikio.
The economic effects of GLP-1s
We estimate the causal impacts of GLP-1 treatment on labor market outcomes using linked Danish administrative data and a matched stacked difference-in-differences design. We compare patients who initiate GLP-1 treatment during the first two years of Semaglutide availability to observably similar patients who initiate four years later. We find that GLP-1 treatment reduces long-term sickness leave by 17.3%. We estimate total fiscal benefits of GLP-1 initiation of approximately 1.3–1.5% of annual labor income per employed individual. We do not detect statistically significant or economically meaningful impacts on income, labor force participation, or employment over four years.
That is from a new NBER working paper by
The Trump Administration’s Threat to Scientific Research
In The Nationalization of American Science I warned that the Trump administration’s rewriting of the seemingly mundane Regulation for Federal Financial Assistance was a tremendous threat to America’s historically successful decentralized system of science funding. Many others are now sounding the alarm.
It’s not surprising that organizations like the AAAS oppose the rule, albeit with unusually strongly worded dissents:
This latest move is a brazen power grab by the Director of the Office of Management and Budget to buck the will of Congress and the American people and will make future discoveries less likely. If this rule becomes final, Americans’ hopes for future cures, national security and economic strength will rely on the scientific sensibilities of the nation’s chief bureaucrat. Alzheimer’s disease will not be cured by a budget analyst from either political party.
But we are now seeing strong pushback from independent thinkers such as:
Grayson Logue writing at The Dispatch:
A sweeping new rule proposed by the Trump administration could remake how that money is awarded and give the president and his political appointees discretion to cancel funding or target recipients for virtually any reason—with little opportunity for recourse.
White House officials argue the new rule is necessary to assert more accountability over federal grantmaking, but observers fear the shift will expand opportunities for politicization, abuse, and even corruption for an administration that has already demonstrated a penchant for using the levers of the federal government to punish partisan enemies and reward ideological allies.
if I was trying to ruin American leadership in scientific research this is pretty much the kind of rule I would write…One of the genuine difficulties with observing the second Trump term is that the assault on state capacity and impartiality has been so multipronged that it is difficult to keep track of everything going on. But these proposed rule changes are monumental and catastrophic.
and Noah Smith:
MAGA’s attack on science is even worse than it looks…despite science’s overwhelming popularity and public trust, Trump and his administration are launching an unprecedented and devastating attack on American science — cutting funding, and forcing science projects to undergo ideological review by government commissars.
It may be that the Trump administration has pushed too far, but my real worry is that we are losing an equilibrium. Science was never completely independent of politics, of course, but even at the worst of times, funding was decentralized and the culture-war material that dominated the headlines was never more than a tiny fraction of the whole. Like an independent judiciary, independent science has been an American virtue. COVID policy, gender policy, and now the Trump administration’s weaponization of these mistakes may have destroyed that equilibrium.
As I wrote in my original post, we are adopting the loser policies of authoritarian nations but those policies are the norm elsewhere for a reason. Centralized control of science is the default because it serves the people in power of whatever party. Decentralization is the fragile exception—a historically unusual achievement that is easier to destroy than rebuild.
Addendum: And here is Andrew Gelman.